SleepScore Labs

SleepScore Labs was originally formed as a joint venture between ResMed, Sharecare, and Pegasus Capital Advisors in 2016. It has since raised independent capital through multiple funding rounds, though current equity distribution is not publicly disclosed. ResMed's foundational technology and Dr. Mehmet Oz's consumer wellness network remain central to the company's origin story.

Revenue comes from two primary streams: consumer-facing sales of sleep improvement programs and hardware like the SleepScore Max tracker, and a B2B licensing model where partners access the company's API and data analytics for product validation. Companies in bedding, fragrance, and nutritional supplements have paid for efficacy studies that use SleepScore's objective dataset to validate how their products improve restorative sleep.

SleepScore's devices use low-power, short-range sonar — essentially echolocation — to detect breathing patterns and body movement without physical contact with the user. The radar-based approach was originally developed for medical-grade sleep apnea screening. The signal processing algorithms parse raw RF reflections into sleep staging, classifying light sleep, deep sleep, and REM, then train a recommendation engine on that structured sleep architecture data.

The firm has stated it has collected an objective dataset exceeding 20 million nights of sleep, gathered from consumers across more than 150 countries over 13 years. This dataset includes raw respiratory rate, movement, and derived sleep-stage labels, making it one of the largest longitudinal sleep databases not controlled by a wearables manufacturer or a pure academic center.

No. While the technology lineage comes from regulated medical device development at ResMed, SleepScore Labs deliberately positions its products in the wellness and consumer health space, avoiding FDA clearance as a diagnostic tool. This regulatory posture allows faster product iteration and direct-to-consumer marketing that a cleared medical device cannot support.